In Vitro Diagnostics Market Set to Reach $241.14 Billion by 2030

The global in vitro diagnostics market is projected to grow from $152.42 billion in 2026 to $241.14 billion by 2030, according to The Business Research Company. Rising cancer cases, broader molecular testing and decentralized diagnostics are driving demand for faster, more precise testing worldwide.

Why it matters: - In vitro diagnostics sit at the center of disease detection, treatment decisions and ongoing patient monitoring. - The market’s expected growth signals stronger demand for lab testing, rapid diagnostics and molecular tools across healthcare systems. - Cancer prevalence is adding pressure for more screening and diagnostic capacity.

What happened: - The Business Research Company published its In Vitro Diagnostics Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Aug. 12, 2026. - The report says the in vitro diagnostics market will rise from $136.55 billion in 2025 to $152.42 billion in 2026. - The report projects the market will reach $241.14 billion by 2030, implying a 12.2% CAGR. - Download a free sample of the report. - View the full market report.

The details: - Historical growth was supported by higher diagnostic testing volumes, expanded infectious disease screening, a heavier chronic disease burden, improved laboratory infrastructure and wider healthcare access. - The report points to decentralized diagnostics, molecular testing investment, personalized medicine diagnostics, faster testing demand and AI-powered diagnostic tools as key growth drivers through 2030. - Emerging trends include point-of-care diagnostic devices, greater use of molecular and immunoassay testing, more automated laboratory systems, multiplex diagnostic platforms and rapid testing capabilities. - In vitro diagnostics are tests run on samples such as blood, tissue or urine outside the body in controlled settings. - These tests use specialized equipment and reagents in laboratories and other clinical environments. - The report says IVDs are essential for detecting disease, guiding treatment and monitoring health conditions over time. - Cancer prevalence is one of the market’s main growth drivers. - Lifestyle factors tied to cancer risk include tobacco use, unhealthy diets, physical inactivity and pollution. - The National Center for Biotechnology Information reported in January 2023 that the U.S. had 1,958,310 new cancer cases and expected 609,820 cancer-related deaths in 2023.

Between the lines: - The forecast suggests diagnostics is shifting toward faster, more decentralized testing rather than relying only on centralized labs. - AI and automation are becoming more important as healthcare systems look for speed, precision and scale. - North America’s lead in 2025 shows the region remains the most mature market, while Asia-Pacific ranks as the second-largest and likely a key growth area.

What's next: - The report expects continued expansion in molecular and immunoassay testing, automated lab systems and point-of-care devices. - Wider adoption of decentralized diagnostics and AI-enabled tools should support market growth through 2030. - The report covers North America, Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa, giving a global view of demand patterns.